カツマタ ヤスヒロ
勝又 康弘 所属 医学部 医学科(東京女子医科大学病院) 職種 講師 |
|
論文種別 | 原著 |
言語種別 | 英語 |
査読の有無 | 査読あり |
表題 | Clinical usefulness of anti-M-type phospholipase-A-receptor antibodies in patients with membranous nephropathy and the comparison of three quantification methods. |
掲載誌名 | 正式名:Immunological medicine 略 称:Immunol Med ISSNコード:25785826/25785826 |
掲載区分 | 国外 |
巻・号・頁 | 43(1),pp.47-56 |
著者・共著者 | Katsumata Yasuhiro, Okamoto Yuko, Moriyama Takahito, Moriyama Rina, Kawamoto Manabu, Hanaoka Masanori, Uchida Keiko, Nitta Kosaku, Harigai Masayoshi |
発行年月 | 2020/03 |
概要 | Associations between anti-M-type phospholipase A2 receptor (PLA2R) antibodies and disease activity and prognosis have been suggested in primary membranous nephropathy (MN); however, more evidence is needed. We aimed to establish a clinically useful method to measure anti-PLA2R antibodies. We developed a western blot assay and a cell-based enzyme-linked immunosorbent assay (ELISA). Anti-PLA2R antibodies were evaluated retrospectively using these assays and the commercial solid-phase ELISA. Anti-PLA2R antibodies were detected in 12, 6, and 12 out of 23 Japanese patients with biopsy-proven primary MN using the western blot, the cell-based ELISA, and the solid-phase ELISA, respectively. The samples of the lupus MN patients tested negative. The levels of proteinuria correlated moderately with the titres of anti-PLA2R antibodies measured by the three methods (r = 0.39-0.47). Anti-PLA2R antibodies were significantly associated with physicians' decisions on immunosuppressive treatment without prior knowledge of anti-PLA2R antibody positivity (p < .01). In the longitudinal analysis, the titres of anti-PLA2R antibodies measured by the solid-phase ELISA declined significantly following treatment (p = .03). In conclusion, these results suggest the usefulness of anti-PLA2R antibody as a diagnostic, prognostic, and surrogate biomarker in primary MN. The three methods proved to be reliable for measuring anti-PLA2R antibody titres, but their performances differ. |
DOI | 10.1080/25785826.2019.1710079 |
PMID | 31910103 |